Introduction
Sjögren's syndrome is a chronic autoimmune disease leading to damage of the exocrine glands, mainly salivary and lacrimal. On histopathology examination inflammatory infiltrations are found, consisting of mononuclear cells with CD4+ T-cell predominance. In laboratory test results the following are found: anti-Ro/SS-A and anti-La/SS-B antibodies, hypergammaglobulinaemia, rheumatoid factor, decreased concentration of C4 complement component and increased values of inflammatory state parameters.
Two forms of Sjögren's syndrome can be distinguished: primary, occurring as a separate disease entity;
Marginal zone B-cell lymphoma in a patient with Sjögren's syndrome and secondary, accompanying other systemic autoimmune diseases. It is estimated that primary Sjögren's syndrome develops in 0.05 to 1% of the population. The prevalence varies significantly, depending on the selection of the study group and accepted classification criteria [1] [2] [3] [4] .
Despite the fact that the disease is associated mainly with symptoms and signs of eye and mouth dryness, the possibility should be kept in mind of involvement of other exocrine glands, e.g. in the alimentary and respiratory systems and other internal organs. The lesions can also develop in the kidneys, joints, blood vessels, nervous system and the skin.
In primary Sjögren's syndrome a significantly higher incidence of lymphoma development is observed, compared with the general population [5] [6] [7] . It is estimated that the 10-year risk of developing a lymphoma in this population is 4% [5] . In these patients, most frequently non-Hodgkin lymphomas develop, mainly marginal zone B-cell lymphomas (MZL), among which splenic B-cell marginal zone lymphoma (SMZL), nodal marginal zone lymphoma (NMZL) and mucosa-associated lymphoid tissue (MALT) lymphoma can be distinguished.
The most frequent locations include the salivary glands, but malignant transformation occur can also in other organs [1, 5] . These tumours usually have a slow and oligosymptomatic course. Table I .
Case report
On the admission to the Department the general condition of the patient was good. She reported dyspnoea, mainly on effort, generalised arthralgia, blanching of the hands and feet due to cold and development of nodular Before the admission to the Department she was treated with prednisone in a 10 mg daily dose. Physical examination revealed the following abnormalities: traction on the region of the jugular notch during breathing, funnel chest, dry rales over the lungs on auscultation, reticular livedo on the lower extremities, enlarged isolated lymph nodes along the sternocleidomastoid muscle, subcutaneous nodules above the left scapula and above the upper lip (of diameter up to 1 cm) and numerous carious defects of the teeth. The examination of peripheral joints, apart from pain on pressure of the knee, ankle and wrist joints, demonstrated no abnormalities.
During the hospitalisation of the patient in the Department chest X-ray examination was performed, which revealed a tissue mass of several centimetres in diameter, bulging into the tracheal lumen, bilateral bronchiectases, dispersed emphysematous bullae and also ground glass areas and small nodules in both lungs, a disintegrating infiltration of 19 × 21 mm dimensions in the 10 th segment of the right lung, and isolated, non-characteristic lymph nodes in the mediastinum, the largest of 4 × 9 mm dimensions (Figs. 1 and 2 ). Bronchofibroscopy demonstrated a polycyclic nodular lesion on the posterior wall of the trachea, about 1 cm below the vocal cords -sections and bronchoalveolar lavage fluid were taken. Besides that a section was taken from the skin lesion above the left scapula.
On laboratory tests the following were found: increased ESR (erythrocyte sedimentation rate) value (57 mm/h) with normal CRP (C-reactive protein) values (3.5 mg/l). The remaining test results were as follows: β2-microglobulin 3.0 mg/l, LDH (lactate dehydrogenase) 224 U/l, C4 complement component 0.02 g/l (normal value 0.1-0.4 g/l), antinuclear antibodies titre 1 : 2560, antibodies: SS-A/Ro 3.85 U/ml (normal value < 0.9 U/ml), SS-B/La 9.88 U/ml (normal value < 0.9 U/ml). No abnormalities were found in peripheral blood count.
In view of planned immunosuppressive treatment and a history of contact with tuberculosis, chemoprophylaxis was administered (isoniazid 300 mg daily) until obtaining of the BAL examination result. During the stay in the Department the patient was given three methylprednisolone pulses (Solu-Medrol) of 500 mg each, obtaining a reduction of dyspnoea and improvement of physical fitness. The next hospitalisation of the patient was scheduled, in order to continue the treatment.
The obtained results of the examinations failed to confirm the diagnosis of granulomatosis with polyangiitis (GPA). Antibodies against cytoplasm of neutrophils were absent. On histological examination of the tracheal lesion biopsy specimen a profuse inflammatory infiltrate was found, without typical inflammatory changes in the blood vessels and epithelial granulomata. In the section taken from the skin lesion on the back, lesions were found, which could have corresponded to marginal zone B-cell lymphoma -an infiltrate of small centrocyte-like lymphocytes (CCL) of phenotype CD20+, CD3-, bcl2+, CD10-, CD15-, Ki67 20% (Figs. 3 and 4) .
The patient was readmitted to the Department in order to assess the degree of lymphoproliferative disease progression and for haematological consultation. In the immunophenotypization of peripheral blood lymphocytes no lymphoma cells were found. All the biopsy specimens taken as yet (sections from the salivary gland, trachea and hard palate) were re-examined -lymphocytic infiltrations were found penetrating and destroying the epithelial structures of the salivary glands, with B-cell phenotype (CD20+, CD3-, bcl2+, absence of Ig k/l).
Based on the whole clinical picture, histological reassessment and immunohistochemical verification, the patient was diagnosed with extranodal marginal zone Ground glass areas and small nodules in both lungs. Isolated, non-characteristic lymph nodes in the mediastinum, the largest of 4 × 9 mm dimensions.
Marginal zone B-cell lymphoma in a patient with Sjögren's syndrome B-cell lymphoma in progression grade IV according to the Ann Arbor classification.
The patient was referred for further treatment in the Department of Haematology, where, in October 2010, the treatment was started according to the R-CVP (cyclophosphamide, vincristine, prednisone, rituximab) regimen. After the first treatment cycle a significant clinical improvement was observed, while after 4 cycles, complete regression of respiratory system changes was demonstrated on control chest CT examination. Regression of the skin lesions was also observed. The patient received altogether six R-CVP chemotherapy cycles, after which maintenance therapy was administered with rituximab in a 375 mg/m 2 dose s.c., administered every two months for two years. The treatment was completed in January 2013. On control chest CT examination (January 2013) complete remission persisted. The patient was referred to the Haematology Outpatient Clinic, University Clinical Centre in Gdańsk for further follow-up.
Discussion
In primary Sjögren's syndrome a significantly higher incidence of lymphomas is observed, compared with a b the general population [5] [6] [7] . In the literature, a relationship has been described between persistent activation of lymphocytes caused by chronic immunological stimulation and their secondary malignant transformation [8, 9] . The relationship between these two disease entities has been reported for several decades. Lymphoproliferative syndromes are currently regarded as the most dangerous complications of Sjögren's syndrome. Ioannidis et al. in a study conducted in 723 patients with Sjögren's syndrome demonstrated that one out of every five fatal cases was due to lymphoma development [5] . The mean time from making the diagnosis of Sjögren's syndrome to the final diagnosis of lymphoma is 7.5 years [7, 10] . The changes can be limited for many years to one location and can undergo spontaneous remissions [10] . The slow and oligosymptomatic progression of the malignant process causes that the diagnosis is frequently made late, even after several years of the disease course; therefore patients with Sjögren's syndrome should be carefully followed up and subjected to frequent follow-up examinations. Patients with such signs as generalised lymphadenopathy, splenomegaly, chronic salivary gland oedema, changes in the respira- tory and nervous systems and skin lesions, and with presence of cryoglobulins, and decreased C4 concentration, belong to the group at higher risk of lymphoma development [2, 4] .
In the clinical case presented, only thorough immunohistochemical analysis of the biopsy specimens revealed the presence of lymphoma cells, while, for several years of the disease course, the histological picture alone failed to give grounds for putting forward a suggestion of a lymphoproliferative disease. Some types of B-cell lymphomas, including extranodal marginal zone lymphoma of MALT type, can resemble reactive lesions, due to slight cellular atypia. The application of immunohistochemical staining, together with the morphological picture and clinical data, make it possible to avoid erroneous diagnoses based exclusively on morphology assessment.
In summary, in patients with Sjögren's syndrome, in whom exacerbation of the disease or its atypical course may indicate development of a lymphoproliferative disease, it is necessary to perform a thorough clinical, imaging, histological and immunohistochemical assessment. The development of diagnostic methods, regular monitoring, correctly directed tests and new therapeutic methods can contribute to an improvement of the prognosis in this group of patients.
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